TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01546051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-1038, BCI-1206 & BCI-1283
Description: Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design
Study: NCT01344772

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: A total hip arthroplasty is performed through a standard posterior approach
Study: NCT01274325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sereflo
Description: Patients take sereflo (25/125) 2 puffs twice a day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Description: Patients will take Seretide (25/125) 2 puffs twice a day for 4 weeks
Study: NCT03913572

Intervention type: PROCEDURE
Intervention: Injection of adipose-derived stem cells into perianal fistula
Description: The plastic surgery team will perform fat graft harvest. Tumescent solution will be infiltrated into the area of liposuction, generally the abdomen, flanks, or thighs. Approximately a00ml of liposuction aspirate will be retrieved. It will be washed and condensed down to about 5-25 ml of good-quality fat graft using the REVOLVE System by Acelity. This will then be loaded into a syringe fitted with an injection cannula. The colorectal surgeon will perform an exam under anesthesia and determine if any additional procedure such as ligation of fistula tract, fistulotomy, endorectal advancement flap, or seton placement/exchange is needed. Severity of disease at time of surgery will be recorded by the attending surgeon. Following any indicated procedure, the lipoaspirate will be injected into the soft tissues around the fistula tract.
Study: NCT05012553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education of self and peer assesment
Description: Stoma care skill achievement is expected to be higher in the group that received self- and peer-assessment training compared to the group that did not receive training.
Study: NCT01546051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-838
Description: BCI-838 900 mg or matching placebo administered as a single oral dose under fasted conditions
Study: NCT02976610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemolysis Point-of-Care test
Description: Hemolysis measurement of plasma using a point of care test to determine the hemolysis level in plasma
Study: NCT02745652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed electromagnetic field
Description: it is a magnetic device for magneto-therapy, it has an appliance, motorized bed, and applicable large solenoids which can be moved in 4 different positions according to the treatment area, and the additional small solenoid for hand treatment with 30 cm diameter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: Ultrasound is applied using a transducer or applicator that is in direct contact with the patient's skin. Gel is a medium which is used on all surfaces of the head to reduce friction and assist transmission of the ultrasonic waves
Study: NCT04179877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPS
Description: Occupational rehabilitation and support Integrated with clinical treatment
Study: NCT02029131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Educated exercise training for the trunk 3 times per week, each for 20 min. Recommendation of additional fitness courses as offered by the local healthy insurance company.
Study: NCT00680329

Intervention type: DRUG
Intervention: Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)
Description: One drop in study eye(s) once daily in the evening for four months

Intervention type: DEVICE
Intervention: Travalert Dosing Aid
Description: Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
Study: NCT01914237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Castor Stent Graft
Description: Endovascular Repair of Aortic Dissection
Study: NCT03319433

Intervention type: DEVICE
Intervention: Perfusion Index
Description: Use of non-invasive pulse oximeter to determine perfusion index
Study: NCT00318721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long Lasting Impregnated Nets (LLIN)
Description: Distribution of LLIN in selected clusters

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Long Lasting Impregnated Nets (LLIN)
Description: Distribution of LLIN in selected clusters
Study: NCT01585077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected mosquito bites
Description: All volunteers will receive one dose of 2-4 P. vivax infected mosquito bites. All the mosquitoes will correspond to the same mosquito batch to make sure that all volunteers receive the same P. vivax strain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected mosquito bites
Description: All volunteers will receive one dose of 2-4 P. vivax infected mosquito bites. All the mosquitoes will correspond to the same mosquito batch to make sure that all volunteers receive the same P. vivax strain.
Study: NCT02663531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DVA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DVA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DVA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDOCT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDOCT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDOCT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pattern ERG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pattern ERG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pattern ERG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Study: NCT04223986

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound
Description: decide between the need for intervention or not (Percutaneous coronary intervention)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Troponin- T quick test
Description: Quick test for Troponin T blood assessment
Study: NCT01641159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone
Description: Study participants will be randomly assigned to receive either buspirone or matching placebo. Following dose escalation, the target at study day 10 is to achieve the highest tolerated dose not exceeding 60 mg. Participants who are unable to reach the 60 mg dose or who need to be reduced from 60 mg due to tolerability will be maintained on 15 mg, 30 mg, or 45 mg, whichever is the highest dose tolerated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will be randomly assigned to receive either buspirone or matching placebo. Placebo tablets will be identical in color and size to the buspirone tablets.
Study: NCT03653208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
Study: NCT02515903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-endoscopic surgery
Description: Intra-endoscopic surgery for evacuation of ICH
Study: NCT03653208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1 (single administration)
Study: NCT01529320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adventan® (methylprednisolone aceponate 0,1%)
Description: Doses: 1/4 FTU (Finger Tip Unit) during 5 days (Day 7-Day 11). Procedure: Patch Test (Nickel sulphate 5%) during 2 days (Day 0- Day 2.
Study: NCT00436605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Study: NCT03934177

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry powder
Description: Dried, powdered blueberries will be consumed at 24 g/day in two divided doses at least 4 hours apart.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: A placebo consisting maltodextrin will be consumed at 24 g/day in two divided doses at least 4 hours apart.
Study: NCT03417570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)
Description: -The second endoscopist will be blinded to the results of the initial exam.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)
Description: -The second endoscopist will be blinded to the results of the initial exam.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus Disposable Distal Attachment Cap
Description: -The second endoscopist will be blinded to the results of the initial exam.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus Disposable Distal Attachment Cap
Description: -The second endoscopist will be blinded to the results of the initial exam.
Study: NCT01409629

Intervention type: BEHAVIORAL
Intervention: Computer game
Description: Participants will play a computer game
Study: NCT01696045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT02736240

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal polysaccharide conjugate vaccine
Study: NCT02416960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Diet Group
Description: This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, low glycemic index/load diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Diet Group
Description: This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, high glycemic index/load diet.
Study: NCT04479228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endosonography guided transmural drainage
Description: The procedures would be performed by experienced endoscopists. All procedures will be performed with the patient in the left lateral position under propofol sedation after administration of intravenous antibiotics (third generation cephalosporins) A therapeutic linear echo-endoscope (UCT-180; Olympus Ltd, Tokyo, Japan) will be used; the PFC assessed for size, wall maturity, thickness, interposing collaterals and percentage of solid debris

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endosonography guided transmural drainage
Description: The procedures would be performed by experienced endoscopists. All procedures will be performed with the patient in the left lateral position under propofol sedation after administration of intravenous antibiotics (third generation cephalosporins) A therapeutic linear echo-endoscope (UCT-180; Olympus Ltd, Tokyo, Japan) will be used; the PFC assessed for size, wall maturity, thickness, interposing collaterals and percentage of solid debris
Study: NCT02158923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver
Description: To start Alveolar Recruitment Maneuver (ARM), change ventilatory pressure-controlled mode (PCV) with 15 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 10 cmH2O. PEEP level will increase 5 on 5 cmH2O every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (25 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver
Description: To start Alveolar Recruitment Maneuver (ARM), change ventilatory pressure-controlled mode (PCV) with 15 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 10 cmH2O. PEEP level will increase 5 on 5 cmH2O every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (25 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calculation of optimal PEEP
Description: Change ventilation mode to volume controlled ventilation (VCV) with a VT of 8 ml / kg, RR 15 rpm and adjust a PEEP of 20 cmH2O. Descend PEEP level 2 by 2 cmH2O every 30 seconds until obtain the best respiratory system compliance (Crs) PEEP. Once you know the optimal level of PEEP (best Crs PEEP), will be conducted again alveolar recruitment maneuver and adjust the best Crs level of PEEP + 2 cmH2O .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calculation of optimal PEEP
Description: Change ventilation mode to volume controlled ventilation (VCV) with a VT of 8 ml / kg, RR 15 rpm and adjust a PEEP of 20 cmH2O. Descend PEEP level 2 by 2 cmH2O every 30 seconds until obtain the best respiratory system compliance (Crs) PEEP. Once you know the optimal level of PEEP (best Crs PEEP), will be conducted again alveolar recruitment maneuver and adjust the best Crs level of PEEP + 2 cmH2O .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative CPAP
Description: Postoperatively, non-invasive mechanical ventilation with a CPAP of 5 cmH2O (or 10 cmH2O if BMI\> 30) with a FiO2 of 0.5 will be applied.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative CPAP
Description: Postoperatively, non-invasive mechanical ventilation with a CPAP of 5 cmH2O (or 10 cmH2O if BMI\> 30) with a FiO2 of 0.5 will be applied.
Study: NCT01986764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be filled with lactose powder.
Study: NCT04549649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual triggering
Description: Adding GnRH agonist (0.2 mg Triptorelin (Decapeptyl; Ferring GmbH) to routine oocyte triggering (two ampoules of Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) is defined as dual triggering.
Study: NCT03260777

Intervention type: DEVICE
Intervention: Trichoscopy
Description: Trichoscopy (hair and scalp dermoscopy) is a noninvasive diagnostic tool that allows the recognition of morphologic structures not visible by the naked eye Structures which may be visualized by trichoscopy include hair shafts of different types, the number of hairs in one pilosebaceous unit, hair follicle openings (dots), the peri and interfollicular areas and the vasculature.

Intervention type: DEVICE
Intervention: Trichoscopy
Description: Trichoscopy (hair and scalp dermoscopy) is a noninvasive diagnostic tool that allows the recognition of morphologic structures not visible by the naked eye Structures which may be visualized by trichoscopy include hair shafts of different types, the number of hairs in one pilosebaceous unit, hair follicle openings (dots), the peri and interfollicular areas and the vasculature.

Intervention type: DEVICE
Intervention: Trichoscopy
Description: Trichoscopy (hair and scalp dermoscopy) is a noninvasive diagnostic tool that allows the recognition of morphologic structures not visible by the naked eye Structures which may be visualized by trichoscopy include hair shafts of different types, the number of hairs in one pilosebaceous unit, hair follicle openings (dots), the peri and interfollicular areas and the vasculature.

Intervention type: DEVICE
Intervention: Trichoscopy
Description: Trichoscopy (hair and scalp dermoscopy) is a noninvasive diagnostic tool that allows the recognition of morphologic structures not visible by the naked eye Structures which may be visualized by trichoscopy include hair shafts of different types, the number of hairs in one pilosebaceous unit, hair follicle openings (dots), the peri and interfollicular areas and the vasculature.
Study: NCT04488523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based Telehealth Intervention
Description: The Family Telehealth intervention focuses on improving parent-child relationships and communication.~For the dyadic version, the intervention involves eleven hours of intervention material; it includes motivational interviews, individual and joint sessions co-led by two separate clinicians. The sessions will be delivered on a weekly basis.~For the caregiver-only version, the intervention involves six hours of intervention material; it includes a motivational interview and individual sessions led by a single clinician. The sessions will be delivered on a weekly basis.
Study: NCT03284203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpiroPD
Description: At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal.
Study: NCT03170687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: short foot cast
Description: metatarsal foot cast

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: short leg cast
Description: full short leg cast
Study: NCT03541200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554
Description: MT-8554 Oral
Study: NCT04237532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine
Description: The mucosal atomizing device will be used intranasally where the sedative drug will be equally divided and sprayed into each nostril while the child semi reclined position.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Dexmedetomidine
Description: The mucosal atomizing device will be used sublingually by asking the child to touch their maxillary incisor teeth with the tip of their tongue and instruct the child not to swallow the drug for 30 seconds.
Study: NCT01217177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study: NCT02515903

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo:stereotactic aspiration surgery
Description: Placebo:stereotactic aspiration surgery for evacuation of ICH
Study: NCT01601769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitom
Description: Patients treated and diagnosed by vitom

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colposcopy
Description: a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.~Patients treated by colposcopy
Study: NCT01217177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study: NCT02893384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthetic Injection above the serratus anterior
Description: This is a quantitative pilot study assessing whether a new technique of local anesthesia injection during mastectomy surgery gives better pain outcomes than the standard methods. Patients who meet inclusion criteria will be invited to partake and all patients will have the injection technique. These patients will then be monitored for pain outcomes up to 7 days following the surgery and the results compared with historical results from patients who have already had the surgery.
Study: NCT03377478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa
Description: Patients testing positive for HCV viremia will receive 12 weeks of Epclusa.
Study: NCT06164977

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous coronary intervention.
Description: Revascularization of chronic total coronary occlusion.
Study: NCT03332186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231
Description: Intravenous infusion administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231
Description: Intravenous infusion administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231
Description: Intravenous infusion administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231
Description: Intravenous infusion administration
Study: NCT02938572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0143-0406
Description: Administered subcutaneously (s.c. under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Administered subcutaneously (s.c. under the skin)
Study: NCT02431312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1800
Description: INO-1800 delivered by EP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1800
Description: INO-1800 delivered by EP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1800
Description: INO-1800 delivered by EP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1800
Description: INO-1800 delivered by EP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1800
Description: INO-1800 delivered by EP
Study: NCT02972268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2mg + Solifenacin 5mg
Description: Tamsulosin 0.2mg + Solifenacin 5mg for 12wks